Glecirasib shows positive ORR for KRASG12C mutated-NSCLC in phase II trial

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

FDA approved Hernexeos (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Different KRAS mutations affect how tumors interact with the immune system, UTSW-led study finds

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT Southwestern Medical Center researchers suggests that different KRAS mutation types can variously impact how cancer cells interact with immune cells, significantly affecting the malignant cells’ behavior.

February 20, 2026

Vol.52 No.07

Cancer Policy

Merck & Co. drug for treating NSCLC awarded FDA priority voucher

FDA has granted sacituzumab tirumotecan (sac-TMT), a trophoblast cell-surface antigen 2 directed antibody-drug conjugate, a priority voucher via the agency’s Commissioner’s National Priority Voucher (CNPV) Pilot Program.

January 09, 2026

Vol.52 No.1

By Claire Marie Porter

Drugs & Targets

FDA approves Rybrevant Faspro for EGFR-mutated NSCLC

FDA approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously administered therapy for patients with epidermal growth factor receptor-mutated non-small cell lung cancer.

January 09, 2026

Vol.52 No.1

Podcast

Otis Brawley looks back on a year of great science and greater challenges

In a year that brought us new KRAS-inhibiting drugs, deepened our understanding of HER2 in breast cancer, and highlighted new potential for mRNA vaccines, the cancer field was also rocked by uncertainty of the future of research funding, equity in cancer delivery, and the integrity of review at FDA.

December 31, 2025

Clinical Roundup

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial.

November 21, 2025

Vol.51 No.43

Glecirasib shows positive ORR for KRASG12C mutated-NSCLC in phase II trial

YOU MAY BE INTERESTED IN

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

Different KRAS mutations affect how tumors interact with the immune system, UTSW-led study finds

Merck & Co. drug for treating NSCLC awarded FDA priority voucher

FDA approves Rybrevant Faspro for EGFR-mutated NSCLC

Otis Brawley looks back on a year of great science and greater challenges

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login